AETC National Coordinating Resource Center

François-Xavier Bagnoud Center

School of Nursing, Rutgers, The State University of New Jersey
65 Bergen Street, 8th floor
Newark, NJ 07101
United States

(973) 972-5141
(973) 972-0397

The AETC National Coordinating Resource Center provides education, training, and capacity building resources for the AETC Program to support the mission to offer timely, high quality, state-of-the-science information to healthcare professionals working with existing and emerging populations affected by HIV.

Principal Investigator
Phone: (973) 972-5141
Fax: (973) 972-0397
Program Director
Phone: (973) 972-6268
Fax: (973) 972-4263
Program Manager
Phone: (973) 972-9225
Marketing Coordinator
Phone: (973) 972-5528

Resources: 42

Title Publish Date Review Date
Assisting HIV Patients Returning to Mexico and Central America / Asistiendo a los Pacientes que Regresan a México y Centroamérica
Resources for Accessibility
Reaching People with HIV in Rural United States
Integrating Mental Health and Substance Use Care into HIV Primary Care Toolkit
Ryan White HIV/AIDS Program (RWHAP) Clinical Conference
Barriers to Curing Hepatitis C Virus among Coinfected People with HIV Infographic
HIV/HCV Co-infection: An AETC National Curriculum
Prescribing nPEP Infographic
Non-Occupational Post-Exposure Prophylaxis (nPEP) Toolkit
Passport to Cure
Hep C Free Postcard
Brand and Generic Names of ARVs in the United States and Mexico
Flyer: Hepatitis C Screening and Treatment in People with HIV
Myths about Providing HCV Treatment to People with HIV with Substance Use Disorder(s)
Prescribing PrEP: A Guide for Healthcare Providers
Rapid (Immediate) ART Initiation & Restart: Guide for Clinicians
Hepatitis C: Getting Cured Is Easier than Ever
Evaluating AETC NCRC Partnerships for Impact
HIV Epidemic Rapid Response Toolkit
COVID-19 Resources for HIV Providers
Conducting a Primary or Acute Care HIV Telemedicine Visit
Direct-acting Antiviral (DAA) Prior Authorization Letter Templates
HHS Adult ART Guidelines: Initial Therapy
HHS Adult ART Guidelines: Transgender People with HIV
HHS Adult ART Guidelines: HIV and ART in Older People
HHS Adult ART Guidelines: Treatment-Experienced Patients
Federal COVID-19 Resources
Results and Response to a 10-State COVID-19 Practice Impact Survey in the Mountain West Region
HIV & SARS-CoV-2 Webinar Series
COVID-19, HIV, and Housing Instability
Self-care, Resiliency, and Stress Management for Healthcare Providers
Risk, Presentation, Treatment, and Outcomes of COVID-19 in People with HIV
Federal Training Centers Collaborative (FTCC) Virtual Learning Session Materials
New Pandemic, Old Inequities: Impacts of COVID-19 and HIV on Marginalized Populations
Post COVID Syndrome: An Overview and Approach to Management
Integrating Behavioral Health into Primary HIV Care — Covering the Bases
Community Health Worker Training Resources
Implementing Substance Use Disorder (SUD) Services in HIV Care Settings Toolkit
U.S. Monkeypox (MPX) - Information and Recommendations
Tips for Managing Digital Design Projects
Quick Guide: CDC HIV Laboratory Testing Recommendations
HIV Care Continuum: Key Resources for HIV Clinicians

Articles: 53

Title Publish date Review date
TargetHIV: New Name, New Look
Tissue Levels of TAF: Too Low for PrEP?
Switching from TDF/FTC to TAF/FTC
PrEP: Bone Density Improves after Stopping TDF/FTC
HIV Meds Update: ART in Acute HIV--Decreasing HIV DNA
HIV Meds Update: Treatment as Prevention: Suppressive ART, Condomless Sex, and HIV Transmission Risk - also a Word on HPTN 052
HIV Meds Update - RAPID: Immediate ART Initiation
HIV Meds Update: PrEP Uptake by Sex, Race, and Age
CROI 2017: Failure of Dolutegravir Monotherapy
CROI 2017: Dolutegravir in 2-Drug Simplification Studies
CROI 2017: Bictegravir and Dolutegravir, Head-to-Head Comparison
CROI 2017: Doravirine Noninferior to Darunavir + Ritonavir in Initial Treatment
Bictegravir in Initial Therapy
Doravirine in Initial Therapy: DRIVE-AHEAD Study
Undetectable = Untransmittable: Effective HIV Treatment Prevents HIV Transmission
Ibalizumab Approved for Persons with Multidrug Resistant HIV
Naltrexone Improves Virologic Suppression
Darunavir/Cobicistat/FTC/TAF Single-Pill Combination in Treatment-Experienced Patients: EMERALD Study
Immediate ART Initiation Improves Time to Viral Suppression
Bictegravir/TAF/FTC in Women
Bictegravir Approved for Initial ART, in Combination with TAF/FTC
Possible Safety Issue with Dolutegravir during Pregnancy: Reports of Neural Tube Defects
Darunavir/Cobicistat/FTC/TAF Coformulation Approved; More Data from EMERALD Switch Study
Dolutegravir + 3TC in Initial Therapy
U=U in PARTNER2 Study of MSM
Doravirine--New NNRTI Approved by FDA
Rapid ART Start
FDA Approves 2-Drug Combination of Dolutegravir + Lamivudine
Long-Acting Injectable ART: Cabotegravir + Rilpivirine
Safety of Dolutegravir at Conception: Updated Data
New ARV Approval - Fostemsavir
Long-acting Injectable PrEP: Cabotegravir
HIV Meds Updates - TANGO and SALSA Studies: Switch to DTG/3TC from 3-Drug ART
HIV Meds Updates - Long-acting Injectable Therapy: Cabotegravir + Rilpivirine
HIV Meds Updates: Long-acting Injectable Therapy: Lenacapavir
Long-acting Injectable PrEP Approved: Cabotegravir
Updated CDC PrEP Guidelines
HIV-related Journal Articles by AETC-Affiliated Researchers and Faculty, 2019-2020
HIV Care Tools – A New Resource for Ending the HIV Epidemic
HIV-related Journal Articles from AETC-Affiliated Researchers and Faculty, 2021
AETC Representation at the 2022 National Ryan White Conference on HIV Care & Treatment
NECA in the Know Special Edition Episode: All about Monkeypox
HIV-related Journal Articles from AETC-Affiliated Researchers and Faculty, 2022
START-ing TEMPRANO: Early Initiation of Antiretroviral Therapy for HIV
Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy
Use of Dolutegravir in Dialysis
On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen
Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)
Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women
Updates in Antiretroviral Treatment during Pregnancy: Dolutegravir in Late Pregnancy
Dolutegravir in Early Pregnancy: Updates on Possible Risk of Neural Tube Defects
Tips for Successful Linkage to Care